Evidence mapPaperPMID 30899530Full record

Trial reportBMJ open diabetes research & care2019

Selenium supplementation and insulin resistance in a randomized, clinical trial.

Elizabeth Theresa Jacobs, Peter Lance, Lawrence J Mandarino, Nathan A Ellis, H-H Sherry Chow, Janet Foote, Jessica A Martinez, Chiu-Hsieh Paul Hsu, Ken Batai, Kathylynn Saboda and 1 more

Registry-linked trialOpen access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in BMJ open diabetes research & care, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00078897 (Phase III Study of the Effects of Selenium on Adenomatous Polyp Recurrence), which is not on this map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00078897 phase3terminatednot on this map

Phase III Study of the Effects of Selenium on Adenomatous Polyp Recurrence

TypeinterventionalSponsorUniversity of ArizonaRan2005 to 2018Enrolled1,621ConditionsColorectal Cancer, Adenomatous Colorectal Polyps, Precancerous ConditionArmsSelenium
3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.

  1. American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2022
    Guideline
  2. Article
  3. Article
  4. Review
  5. Article
  6. Selenium Species in Diabetes Mellitus Type 2.Biological trace element research · 2024
    Review
  7. Review
  8. Scientific opinion on the tolerable upper intake level for selenium.EFSA journal. European Food Safety Authority · 2023
    Article
  9. Review
  10. Review
  11. The Role of Selenium in Pathologies: An Updated Review.Antioxidants (Basel, Switzerland) · 2022
    Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Elizabeth Theresa Jacobs *Department of Epidemiology and Biostatistics, Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, Arizona.
Peter Lance *University of Arizona Cancer Center, Tucson, Arizona.
Lawrence J MandarinoDepartment of Medicine, University of Arizona, Tucson, Arizona.
Nathan A EllisUniversity of Arizona Cancer Center, Tucson, Arizona.
H-H Sherry ChowUniversity of Arizona Cancer Center, Tucson, Arizona.
Janet FooteDepartment of Epidemiology and Biostatistics, Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, Arizona.
Jessica A MartinezUniversity of Arizona Cancer Center, Tucson, Arizona.
Chiu-Hsieh Paul HsuDepartment of Epidemiology and Biostatistics, Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, Arizona.
Ken BataiDepartment of Surgery, University of Arizona, Tucson, Arizona.
Kathylynn SabodaUniversity of Arizona Cancer Center, Tucson, Arizona.
Patricia A ThompsonDepartment of Medicine, Stony Brook University, New York City, New York, USA.
University of Arizona · USUniversity of Arizona Cancer CenterStony Brook University · US

Funding

VITAMIN AP30CA023074 · UNIVERSITY OF ARIZONA · 1985 to 2025
$23.1M
WHEAT BRAN FIBER SUPPLEMENTS ON THE RECURRENCE OF COLONIC ADENOMASP01CA041108 · UNIVERSITY OF ARIZONA · 1986 to 2005
$22.3M
SOUTHWEST ENVIRONMENTAL HEALTH SCIENCES CENTERP30ES006694 · UNIVERSITY OF ARIZONA · 1994 to 2025
$7.3M
Opioid use disorders in adolescents: predictors of treatment and outcomesR01DA047396 · NIDA · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI DOUGLAS L. LESLIE · 2021 to 2021
$570k
NCI NIH HHS P01 CA041108NCI NIH HHS P30 CA023074NCI NIH HHS R01 CA151708NIDA NIH HHS R01 DA047396NIEHS NIH HHS P30 ES006694
6 · The paper itself

Abstract

Objective: While controversial, observational and randomized clinical trial data implicate the micronutrient selenium (Se) in the development of type 2 diabetes (T2D). The aim of this study was to test the hypothesis that Se supplementation adversely affects pancreatic β-cell function and insulin sensitivity. Research design and methods: In a subset of 400 individuals participating in a randomized, placebo-controlled trial of Se at 200 µg/day for colorectal adenomatous polyps, fasting plasma glucose and insulin were measured before randomization and within 6 months of completing intervention. Change in the homeostasis model assessment-β cell function (HOMA2-%β) and insulin sensitivity (HOMA2-%S) were compared between arms. A subgroup of 175 (79 Se and 96 placebo) participants underwent a modified oral glucose tolerance test (mOGTT) at the end of intervention and change in glucose values was assessed. Results: No statistically significant differences were observed for changes in HOMA2-%β or HOMA2-%S between those who received Se compared with placebo. After a mean of 2.9 years on study, mean HOMA2-%β values were 3.1±24.0 and 3.1±29.8 for the Se and placebo groups, respectively (p=0.99). For HOMA2-%S, the values were -0.5±223.2 and 80.9±1530.9 for the Se and placebo groups, respectively (p=1.00). Stratification by sex or age did not reveal any statistically significant effects on insulin sensitivity by treatment group. For mOGTT, mean baseline fasting blood glucose concentrations were significantly higher among participants in the placebo group compared with the Se group (96.6±14.6 and 92.3±12.0, respectively; p=0.04), a trend which remained through the 20 min assessment. Conclusions: These findings do not support a significant adverse effect of daily Se supplementation with 200 µg/day of selenized yeast on β-cell function or insulin sensitivity as an explanation for previously reported associations between Se and T2D. Further clarification of longer term effects of Se is needed. Clinical trial registry: NIH Clinical Trials.gov number NCT00078897.

Indexed as

AdenomaAdultAgedAged, 80 and overColorectal NeoplasmsDietary SupplementsFemaleHumansInsulin ResistanceInsulin-Secreting CellsMaleMiddle AgedPolypsSeleniumSeleniumHOMAhomeostatic model assessmentinsulin resistanceOGTTseleniumsupplementation

Identifiers

PMID30899530
PMCPMC6398811
OpenAlexW2912097322

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.